One Wall Street analyst on the 2018 earnings call for Boston Scientific Corp. (NYSE:BSX) wondered if the Marlborough, Mass.-based med-tech giant had bitten off more than it could chew with its 10 disclosed acquisitions from last year that were worth more than $6.4 billion. The largest deal by far was announced in late November for British interventional oncology company Btg plc for $4.2 billion; that acquisition is expected to close during the first half of 2019. Read More
